PressOctober 19, 2022 Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland
BlogOctober 19, 2022 What Does the Future of Psychedelics Look Like?: A Mindshifting Moments Special Event
PressOctober 18, 2022 atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
PressOctober 18, 2022 Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
PressOctober 18, 2022 Silo Pharma Stock Higher After Investors Appraise Innovative Treatment For Nerve Pain And Neurological Disorders
PressOctober 18, 2022 Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio
PressOctober 18, 2022 Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
PressOctober 17, 2022 European University to Fund Core One Labs Akome Advanced Neurogenesis Stimulation Studies
PressOctober 16, 2022 Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
PressOctober 14, 2022 Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
PressOctober 14, 2022 Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants
PressOctober 14, 2022 Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
PressOctober 13, 2022 Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022
PressOctober 13, 2022 PSYC’s Spotlight Media Highlights Revenue Growth and Other Operational Achievements Met in Q3
PressOctober 13, 2022 IntelGenx Says Atai Life Sciences Collaboration Leads to Start of First-in-Human Clinical Study of Oral Thin Film Psychedelic Drug Candidate
PressOctober 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
